Judith G Villablanca
Affiliation: University of Southern California
- Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupJudith G Villablanca
Children s Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA
Clin Cancer Res 17:6858-66. 2011..To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma...
- Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I studyMin H Kang
Cancer Center and Departments of Cell Biology and Biochemistry, Pharmacology and Neuroscience, Pediatrics, and Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, STOP 9445 79430 Lubbock, TX, USA
BMC Res Notes 7:256. 2014....
- Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709)Judith G Villablanca
Children s Hospital Los Angeles and the Department Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, USA
J Clin Oncol 24:3423-30. 2006..To determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors...
- Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay
Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
J Nucl Med 53:1155-63. 2012..Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-MIBG, with secondary aims of assessing tumor and organ dosimetry and overall response...
- Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology groupGregory A Yanik
Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
J Nucl Med 54:541-8. 2013..A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for a cohort of patients with high-risk metastatic disease...
- Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I studyKatherine K Matthay
Department of Pediatrics, University of California, San Francisco, 505 Parnassus, M647, San Francisco, CA 94143 0106, USA
J Clin Oncol 27:1020-5. 2009..The goal was to determine the maximum-tolerated dose of (131)I-MIBG in two consecutive infusions at a 2-week interval, supported by autologous stem-cell rescue (ASCR) 2 weeks after the second dose...
- Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastomaAlekist Quach
Department of Pediatrics, UCSF Children s Hospital, University of California, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 56:191-201. 2011..The aim of our study was to analyze the effects of (131) I-MIBG therapy on thyroid and liver function...
- Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium StudyKatherine K Matthay
Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
J Clin Oncol 24:500-6. 2006..To determine the maximum-tolerated dose (MTD) and toxicity of iodine-131-metaiodobenzylguanidine ((131)I-MIBG) with carboplatin, etoposide, melphalan (CEM) and autologous stem-cell transplantation (ASCT) in refractory neuroblastoma...
- Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park
Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
Pediatr Blood Cancer 52:44-50. 2009..The components of therapy required for patients with INSS Stage 3 neuroblastoma and high-risk features remain controversial...
- A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk NeuroblastomaJudith G Villablanca
Department of Pediatrics, Children s Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California
Pediatr Blood Cancer 63:1349-56. 2016..Buthionine sulfoximine (BSO), a GSH synthesis inhibitor, enhances melphalan activity against neuroblastoma cell lines, providing the rationale for a Phase 1 trial of BSO-melphalan...
- Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trialSteven G DuBois
Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
Clin Cancer Res 18:2679-86. 2012..Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan...
- The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastomaAraz Marachelian
Department of Pediatrics, Children s Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California, USA
Pediatr Blood Cancer 58:675-81. 2012..To describe the serial histopathology of intermediate risk stage 3 neuroblastoma after chemotherapy, and correlate with residual mass at therapy completion and outcome...
- Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovaryAnat Erdreich-Epstein
Department of Pediatrics, Childrens Hospital Los Angeles, Keck School of Medicine, California 90027, USA
J Pediatr Hematol Oncol 24:229-33. 2002..She tolerated therapy well and is in complete remission 69 months after her recurrence...
- Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiationSoumen Khatua
Neural Tumors Program, Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles, Los Angeles, California, USA
Pediatr Blood Cancer 55:42-6. 2010..The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas...
- Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010Alexa E Gozali
Children s Center for Cancer and Blood Diseases, Children s Hospital, Los Angeles, CA, USA
Pediatr Blood Cancer 58:905-9. 2012..We have investigated the clinical features and overall survival of all CPT patients treated at Children's Hospital Los Angeles (CHLA) over a 20-year period, with particular attention to the association of CPT with LFS...
- Retinoid therapy of high-risk neuroblastomaC Patrick Reynolds
Division of Hematology Oncology, Children s Hospital of Los Angeles and the University of Southern California Keck School of Medicine, Los Angeles, CA 90054, USA
Cancer Lett 197:185-92. 2003..Thus, further clinical trials of 4-HPR in neuroblastoma, and of 4-HPR in combination with ceramide modulators, are warranted...
- Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastomaShahab Asgharzadeh
Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
J Clin Oncol 30:3525-32. 2012..In this study, we investigated the hypothesis that expression of genes related to tumor-associated inflammatory cells correlates with the observed differences in survival by age at diagnosis and contributes to a prognostic signature...
- Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experienceRima F Jubran
Department of Pediatrics, University of Southern California Keck School of Medicine and Children s Hospital Los Angeles, Los Angeles California, USA
J Pediatr Hematol Oncol 26:31-4. 2004..Patients with extraocular retinoblastoma who achieve remission may benefit from consolidation of their therapy with autologous bone marrow transplant...
- A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomasRoger J Packer
Center for Neuroscience and Behavioral Medicine, Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
Cancer 104:1968-74. 2005..The objective of this Phase I study was to determine the toxicity and feasibility of delivering RMP-7 and carboplatin for 5 successive days during radiotherapy to children with newly diagnosed, diffuse, intrinsic brainstem gliomas...
- Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomasRoger J Packer
Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
Cancer 104:1281-7. 2005..The goal of the current Phase I study was to determine the toxicity and feasibility of delivering RMP-7 and carboplatin for 5 successive days during radiotherapy...